Inhibrx Biosciences, Inc. cash flow statement

In fiscal 2025, Inhibrx Biosciences, Inc.'s operations generated −$130m of cash; it spent $31,000 on capital projects, leaving free cash flow of −$130m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inhibrx Biosciences, Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−193	−194	−130
Depreciation and amortisation	1	2	2
Stock-based pay	25	59	11
Capital spending	5	3	0
Free cash flow	−198	−197	−130
Free cash flow after stock pay	−223	−256	−141

US$ millions unless shown otherwise. Fiscal quarters.

Inhibrx Biosciences, Inc.: cash flow statement, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Cash from operations	−57	−30	−44	−36	−30	−34	−30	−30
Depreciation and amortisation	0	1	1	1	1	1	1	1
Stock-based pay	46	3	3	2	3	3	3	3
Capital spending	1	0	0	0	0	0	0	0
Free cash flow	−59	−31	−44	−36	−30	−34	−30	−30
Free cash flow after stock pay	−105	−33	−47	−38	−33	−37	−33	−33

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DARE vs INBX INBX vs LGVN INBX vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inhibrx Biosciences, Inc.